This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Adaptimmune Therapeutics’s 8K filing here.
Adaptimmune Therapeutics Company Profile
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.
See Also
- Five stocks we like better than Adaptimmune Therapeutics
- What Are Dividend Contenders? Investing in Dividend Contenders
- Aurora Innovation’s Driverless Tech Is Driving Investor Buzz
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Why Aehr Test Systems Could Be a Hidden AI Semiconductor Winner
- Are Penny Stocks a Good Fit for Your Portfolio?
- Get Ahead of the January Effect With These 2 Fintech Stocks
